This review found that available fibrosis marker panels have acceptable performance for identifying significant fibrosis and cirrhosis in human immunodeficiency virus/hepatitis C virus coinfected patients, but were not yet adequate to replace liver biopsy. This was generally a well conducted review. The authors' conclusions are likely to be reliable.
Study selection
Studies that evaluated the accuracy of a panel of serum markers for the prediction of fibrosis in HIV/HCV coinfected patients that used liver biopsy as the reference standard were eligible for inclusion. Studies had to include more than 30 patients and report sufficient data to allow construction of a 2x2 table of test performance. Studies that included other liver diseases were eligible if data could be extracted separately for patients with HIV/HCV coinfection. The primary outcome was identification of significant fibrosis (defined as METAVIR stages F2-4 or Ishak stages F3-6). Prediction of cirrhosis was also considered.
Four studies assessed aspartate aminotransferase (AST)-platelet ratio index (APRI). Two studies assessed Forns' index. FibroTest and SHASTA index were each assessed in single studies. Median patient age was 40 years. The proportion of males was 77%. Nearly all patients were on antiretroviral therapy. Median CD4 count was 429/mm 3 .
Two reviewers independently assessed studies for inclusion. Disagreements were resolved through consensus.
Assessment of study quality
Two reviewers independently assessed study quality using QUADAS. Disagreements were resolved through consensus.
Data extraction
Two reviewers independently extracted data as 2x2 tables of test performance for each threshold reported in the study. Disagreements were resolved through consensus.
Methods of synthesis
Summary sensitivity and specificity together with 95% confidence intervals (CI) were estimated using the bivariate model for studies that reported on single tests at consistent thresholds. Summary receiver operating characteristic (SROC) curves were constructed using the methods of Moses et al. Summary diagnostic odds ratios (DORs) together with 95% CIs were estimated using DerSimonian and Laird random-effects models. Meta-regression was used to examine the impact of fibrosis measure, study quality, patient characteristics and reference standard on test performance. Publication bias was assessed using a regression-based test of funnel plot asymmetry.
